Denosumab (Drug Plan Submission)

Details

Files

Generic Name:

Project Status:

Complete

Therapeutic Area:

Prevention of skeletal-related events due to bone metastases from other solid tumors (excluding breast and prostate cancer), including non-small cell lung cancer

Manufacturer:

Amgen Canada Inc.

Call for patient/clinician input open:

April 27, 2015

Brand Name:

Xgeva

Project Line:

Reimbursement Review

Project Number:

SR0433-001

Call for patient/clinician input closed:

June 16, 2015

NOC Status at Filing:

Post NOC

Performance Metric:

Achieved

Submission Type:

Drug Plan Initiated

Indications:

Prevention of skeletal-related events due to bone metastases from other solid tumors (excluding breast and prostate cancer), including non-small cell lung cancer

Recommendation Type:

List with clinical criteria and/or conditions

Final Recommendation:

March 23, 2016